Scinai Immunotherapeutics Ltd.

Jerusalem BioPark, 2^nd Floor

Hadassah Ein Kerem Campus

Jerusalem, Israel

September 29, 2025

VIA EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Attention: Doris Stacey Gama

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Scinai Immunotherapeutics Ltd. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form F-1 (File No. 333- 290437) so that it will be declared effective at 3:00 p.m., Eastern Standard Time, on September 30, 2025, or as soon thereafter as is practicable.

Should you have any questions regarding this letter, please do not hesitate to contact Perry Wildes, Adv., at +972 (3) 607-4444 or perry.wildes@goldfarb.com, of Goldfarb Gross Seligman & Co., counsel to the Company.